Novo-rivals omsætning banker op – men Trump-aftale koster
Full story
Eli Lilly, a rival of Novo, released a new financial report showing growth for the American drug company. The report indicates increased revenues compared to previous periods. A separate agreement involving Donald Trump, which Novo also participated in, affected the earnings figures.
Novo-konkurrenten Eli Lilly kan igen præsentere et regnskab, der viser vokseværk hos den amerikanske medicinalkæmpe. En aftale med Donald Trump, som Novo også tilsluttede sig, har dog smittet af på indtjeningen.